These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 18240866

  • 1. Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen.
    Autar RS, Boyd MA, Wit FW, Ruxrungthams K, Sankote J, Lange J, Cooper DA, Phanuphak P, Burger DM, Reiss P.
    Antivir Ther; 2007; 12(8):1265-71. PubMed ID: 18240866
    [Abstract] [Full Text] [Related]

  • 2. Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz.
    Boyd MA, Carr A, Ruxrungtham K, Srasuebkul P, Bien D, Law M, Wangsuphachart S, Krisanachinda A, Lerdlum S, Lange JM, Phanuphak P, Cooper DA, Reiss P.
    J Infect Dis; 2006 Sep 01; 194(5):642-50. PubMed ID: 16897663
    [Abstract] [Full Text] [Related]

  • 3. Switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in HIV-infected adults: the Monarch randomized controlled trial.
    Guaraldi G, Zona S, Cossarizza A, Vernacotola L, Carli F, Lattanzi A, Nardini G, Orlando G, Garlassi E, Termini R, Garau M.
    Int J STD AIDS; 2014 Mar 01; 25(3):207-12. PubMed ID: 24216034
    [Abstract] [Full Text] [Related]

  • 4. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
    Young J, Weber R, Rickenbach M, Furrer H, Bernasconi E, Hirschel B, Tarr PE, Vernazza P, Battegay M, Bucher HC.
    Antivir Ther; 2005 Mar 01; 10(5):585-91. PubMed ID: 16152752
    [Abstract] [Full Text] [Related]

  • 5. Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009.
    Boyd MA, Siangphoe U, Ruxrungtham K, Duncombe CJ, Stek M, Lange JM, Cooper DA, Phanuphak P.
    HIV Med; 2005 Nov 01; 6(6):410-20. PubMed ID: 16268823
    [Abstract] [Full Text] [Related]

  • 6. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
    Di Giambenedetto S, Fabbiani M, Colafigli M, Ciccarelli N, Farina S, Sidella L, D'Avino A, Mondi A, Cingolani A, Tamburrini E, Murri R, Navarra P, Cauda R, De Luca A.
    J Antimicrob Chemother; 2013 Jun 01; 68(6):1364-72. PubMed ID: 23372058
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine.
    Bernardino JI, Pulido F, Martinez E, Arrizabalaga J, Domingo P, Portilla J, Ocampo A, Muñoz J, Torres R, Arribas JR, GESIDA-6008-KRETA Study Group.
    J Antimicrob Chemother; 2013 Jun 01; 68(6):1373-81. PubMed ID: 23386261
    [Abstract] [Full Text] [Related]

  • 10. The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy.
    Pérez-Molina JA, Domingo P, Martínez E, Moreno S.
    J Antimicrob Chemother; 2008 Aug 01; 62(2):234-45. PubMed ID: 18480167
    [Abstract] [Full Text] [Related]

  • 11. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST, Eaton SA, Bain AM, Rahman AP, Payne KD, Bedimo R, Herrington JD, Maclayton DO, Rodriguez-Barradas MC, Busti AJ.
    Pharmacotherapy; 2008 Mar 01; 28(3):323-30. PubMed ID: 18294112
    [Abstract] [Full Text] [Related]

  • 12. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
    Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ, Ruiz NM.
    N Engl J Med; 1999 Dec 16; 341(25):1865-73. PubMed ID: 10601505
    [Abstract] [Full Text] [Related]

  • 13. Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy.
    Calmy A, Carey D, Mallon PW, Wand H, Law M, Cooper DA, Carr A, INITIO Trial International Co-ordinating Committee, HAMA study coordination team.
    HIV Med; 2008 Feb 16; 9(2):101-10. PubMed ID: 18257772
    [Abstract] [Full Text] [Related]

  • 14. Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults.
    Carr A, Ritzhaupt A, Zhang W, Zajdenverg R, Workman C, Gatell JM, Cahn P, Chaves R.
    AIDS; 2008 Nov 12; 22(17):2313-21. PubMed ID: 18981770
    [Abstract] [Full Text] [Related]

  • 15. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
    De Luca A, Cozzi-Lepri A, Antinori A, Zaccarelli M, Bongiovanni M, Di Giambenedetto S, Marconi P, Cicconi P, Resta F, Grisorio B, Ciardi M, Cauda R, Monforte Ad, I.Co.N.A, UCSC, IMIT-MI, INMI.
    Antivir Ther; 2006 Nov 12; 11(5):609-18. PubMed ID: 16964829
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors.
    Panagopoulos P, Tsiodras S, Antoniadou A, Katsarolis I, Papadopoulos A, Poulakou G, Giamarellou H.
    Clin Microbiol Infect; 2006 May 12; 12(5):486-9. PubMed ID: 16643529
    [Abstract] [Full Text] [Related]

  • 17. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
    Negredo E, Miró O, Rodríguez-Santiago B, Garrabou G, Estany C, Masabeu A, Force L, Barrufet P, Cucurull J, Domingo P, Alonso-Villaverde C, Bonjoch A, Morén C, Pérez-Alvarez N, Clotet B, MULTINEKA Study Group.
    Clin Infect Dis; 2009 Sep 15; 49(6):892-900. PubMed ID: 19663689
    [Abstract] [Full Text] [Related]

  • 18. Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).
    Tebas P, Zhang J, Yarasheski K, Evans S, Fischl MA, Shevitz A, Feinberg J, Collier AC, Shikuma C, Brizz B, Sattler F, AIDS Clinical Trials Group (ACTG).
    J Acquir Immune Defic Syndr; 2007 Jun 01; 45(2):193-200. PubMed ID: 17527093
    [Abstract] [Full Text] [Related]

  • 19. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
    Neukam K, Mira JA, Ruiz-Morales J, Rivero A, Collado A, Torres-Cornejo A, Merino D, de Los Santos-Gil I, Macías J, González-Serrano M, Camacho A, Parra-García G, Pineda JA, SEGURIDAD HEPÁTICA Study Team of the Grupo HEPAVIR de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI).
    J Antimicrob Chemother; 2011 Nov 01; 66(11):2605-14. PubMed ID: 21903660
    [Abstract] [Full Text] [Related]

  • 20. Short communication metabolic and mitochondrial effects of switching antiretroviral-experienced patients to enfuvirtide, tenofovir and saquinavir/ritonavir.
    Miró O, Garrabou G, López S, Deig E, Vidal I, Infante AB, Cardellach F, Casademont J, Pedrol E.
    Antivir Ther; 2006 Nov 01; 11(5):625-30. PubMed ID: 16964831
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.